Abstract
It is believed that the production and accumulation of beta-amyloid (Aβ) peptide is a critical step to the pathogenesis of Alzheimers disease (AD). BACE 1 (beta-site APP-cleaving enzyme 1 or β-secretase), the key enzyme required for generating Aα from the β-amyloid precursor protein (APP), is regarded as an ideal target for AD therapeutic drug design. Due to low oral bioavailability, metabolic instability and poor ability to penetrate the central nervous system (CNS) of the existing peptidomimetic inhibitors, researchers have paid more attention to the development of nonpeptidomimetic inhibitors in recent years. A number of drug screening approaches and technologies have been used to identify novel nonpeptidomimetic BACE 1 inhibitors. This review mainly focuses on the recent developments in structure-based design and synthesis of the nonpeptidomimetic BACE 1 inhibitors.
Keywords: Alzheimer's disease (AD), nonpeptidomimetic inhibitors, BACE 1 inhibitor
Current Medicinal Chemistry
Title: Progress in the Development of Nonpeptidomimetic BACE 1 Inhibitors for Alzheimers Disease
Volume: 16 Issue: 14
Author(s): Wen-Hai Huang, Rong Sheng and Yong-Zhou Hu
Affiliation:
Keywords: Alzheimer's disease (AD), nonpeptidomimetic inhibitors, BACE 1 inhibitor
Abstract: It is believed that the production and accumulation of beta-amyloid (Aβ) peptide is a critical step to the pathogenesis of Alzheimers disease (AD). BACE 1 (beta-site APP-cleaving enzyme 1 or β-secretase), the key enzyme required for generating Aα from the β-amyloid precursor protein (APP), is regarded as an ideal target for AD therapeutic drug design. Due to low oral bioavailability, metabolic instability and poor ability to penetrate the central nervous system (CNS) of the existing peptidomimetic inhibitors, researchers have paid more attention to the development of nonpeptidomimetic inhibitors in recent years. A number of drug screening approaches and technologies have been used to identify novel nonpeptidomimetic BACE 1 inhibitors. This review mainly focuses on the recent developments in structure-based design and synthesis of the nonpeptidomimetic BACE 1 inhibitors.
Export Options
About this article
Cite this article as:
Huang Wen-Hai, Sheng Rong and Hu Yong-Zhou, Progress in the Development of Nonpeptidomimetic BACE 1 Inhibitors for Alzheimers Disease, Current Medicinal Chemistry 2009; 16 (14) . https://dx.doi.org/10.2174/092986709788186174
DOI https://dx.doi.org/10.2174/092986709788186174 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Insulin-Degrading Enzyme: A Link Between Alzheimer’s and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Electrochemical Biosensor for the Detection of Glycated Albumin
Current Alzheimer Research Therapeutic Opportunities for Trophic Factors in Brain Inflammation
Current Pharmaceutical Analysis Ajmalicine and its Analogues Against AChE and BuChE for the Management of Alzheimer’s Disease: An <i>In-silico</i> Study
Current Pharmaceutical Design Estrogen Receptors as Targets for Drug Development for Breast Cancer, Osteoporosis and Cardiovascular Diseases
Current Cancer Drug Targets Reduction of Oxidative/Nitrosative Stress in Brain and its Involvement in the Neuroprotective Effect of n-3 PUFA in Alzheimer’s Disease
Current Alzheimer Research Unraveling the Complexity of Amyotrophic Lateral Sclerosis: Recent Advances from the Transgenic Mutant SOD1 Mice
CNS & Neurological Disorders - Drug Targets Potential Therapeutic Effects of Oleuropein Aglycone in Alzheimer's Disease
Current Pharmaceutical Biotechnology Ocular Biomarkers of Alzheimer’s Disease
Central Nervous System Agents in Medicinal Chemistry Platelet Alpha- and Beta- Secretase Activities are not Significantly Affected by Dementia or Mild Cognitive Impairment in Swedish Patients
Current Alzheimer Research 2,4,6-Trichlorophenylhydrazine Schiff Bases as DPPH Radical and Super Oxide Anion Scavengers
Medicinal Chemistry Recent Insights into the Involvement of Progranulin in Frontotemporal Dementia
Current Neuropharmacology Quantitative and Mechanistic Studies of Aβ Immunotherapy
CNS & Neurological Disorders - Drug Targets The Influence of Genetic Variations and Drug Interactions Based on Metabolism of Antidepressants and Anticonvulsants
Current Drug Metabolism Recent Progress in Cerebrovascular Gene Therapy
Current Neurovascular Research Editorial [Hot Topic:Gamma-Secretase Inhibitors and Modulators as a Therapeutic Approach to Alzheimers disease (Guest Editor: Bruno P. Imbimbo)]
Current Topics in Medicinal Chemistry Therapeutic Gene Products Delivery by Neuron Stem Cells
Current Pharmaceutical Biotechnology Therapeutic Targets for the Management of Peripheral Nerve Injury- Induced Neuropathic Pain
CNS & Neurological Disorders - Drug Targets Diabetes and Periodontal Diseases: Interplay and Links
Current Diabetes Reviews Genetically-mediated Grey and White Matter Alteration in Normal Elderly Individuals with the CLU-C Allele Gene
Current Alzheimer Research